| Literature DB >> 23203038 |
Jong H Kim1, Perng-Kuang Chang, Kathleen L Chan, Natália C G Faria, Noreen Mahoney, Young K Kim, Maria de L Martins, Bruce C Campbell.
Abstract
Natural compounds that pose no significant medical or environmental side effects are potential sources of antifungal agents, either in their nascent form or as structural backbones for more effective derivatives. Kojic acid (KA) is one such compound. It is a natural by-product of fungal fermentation commonly employed by food and cosmetic industries. We show that KA greatly lowers minimum inhibitory (MIC) or fungicidal (MFC) concentrations of commercial medicinal and agricultural antifungal agents, amphotericin B (AMB) and strobilurin, respectively, against pathogenic yeasts and filamentous fungi. Assays using two mitogen-activated protein kinase (MAPK) mutants, i.e., sakA∆, mpkC∆, of Aspergillus fumigatus, an agent for human invasive aspergillosis, with hydrogen peroxide (H(2)O(2)) or AMB indicate such chemosensitizing activity of KA is most conceivably through disruption of fungal antioxidation systems. KA could be developed as a chemosensitizer to enhance efficacy of certain conventional antifungal drugs or fungicides.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23203038 PMCID: PMC3509554 DOI: 10.3390/ijms131113867
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure of kojic acid (KA).
Fungal strains used in this study.
| Fungal strains | Strain characteristics | Source/Reference |
|---|---|---|
|
| ||
| Kojic acid producer, Human pathogen (aspergillosis), Plant pathogen | NRRL | |
| Kojic acid producer, Plant pathogen | NRRL | |
| Human pathogen (aspergillosis), Reference clinical strain | [ | |
| Human pathogen (aspergillosis), MAPK mutant derived from AF293 | [ | |
| Human pathogen (aspergillosis), MAPK mutant derived from AF293 | [ | |
| Human pathogen (aspergillosis), Clinical isolate | CDC | |
| Human pathogen (aspergillosis), Clinical isolate | CDC | |
| Human pathogen (aspergillosis), Clinical isolate | CDC | |
|
| ||
|
| ||
| Human pathogen (candidiasis), Reference clinical strain | ATCC | |
| Human pathogen (candidiasis), Clinical isolate | IHMT | |
| Human pathogen (candidiasis), Reference clinical strain | ATCC | |
| Human pathogen (candidiasis), Clinical isolate | IHMT | |
| Human pathogen (candidiasis), Clinical isolate | IHMT | |
| Human pathogen (cryptococcosis), Clinical isolate | IHMT | |
| Model yeast, Parental strain ( | SGD | |
| MAPK mutant derived from BY4741 | SGD | |
| MAPK kinase kinase mutant derived from BY4741 | SGD | |
NRRL, National Center for Agricultural Utilization and Research, USDA-ARS, Peoria, IL, USA.
CDC, Centers for Disease Control and Prevention, Atlanta, GA, USA.
ATCC, American Type Culture Collection, Manassas, VA, USA.
IHMT, Instituto de Higiene e Medicina Tropical/CREM, Universidade Nova de Lisboa, Portugal.
SGD, Saccharomyces Genome Database [19].
Figure 2Agar bioassay showing antifungal chemosensitization of kojic acid (KA) with H2O2 tested against Aspergillus strains. Numbers (0–100) indicate percent (%) radial growth compared to non-treated control (100%; no H2O2 and no KA). (−), w/o KA; (+), w/KA (5 mM).
Antifungal chemosensitization of kojic acid (mM) with H2O2 (mM) tested against Aspergillus strains. a Minimum fungicidal concentrations (MFCs) are concentrations where ≥99.9% fungal death was achieved.
| Strains | Compounds | MIC alone | MIC combined | FICI | MFC alone | MFC combined | FFCI |
|---|---|---|---|---|---|---|---|
| Kojic | >12.8 | 0.8 | >12.8 | 0.8 | |||
| AF293 | H2O2 | 8 | 4 | 8 | 4 | ||
| Kojic | >12.8 | 12.8 | 1.0 | >12.8 | 12.8 | 1.0 | |
| H2O2 | 4 | 2 | 4 | 2 | |||
| Kojic | >12.8 | 12.8 | 1.0 | >12.8 | 12.8 | 1.0 | |
| H2O2 | 4 | 2 | 4 | 2 | |||
| Kojic | >12.8 | 6.4 | 0.8 | >12.8 | 12.8 | 0.8 | |
| UAB673 | H2O2 | 2 | 1 | 4 | 1 | ||
| Kojic | >12.8 | 6.4 | 0.8 | >12.8 | 12.8 | 1.0 | |
| UAB680 | H2O2 | 2 | 1 | 2 | 1 | ||
| Kojic | >12.8 | 6.4 | 0.8 | >12.8 | 12.8 | 1.0 | |
| UAB698 | H2O2 | 2 | 1 | 2 | 1 | ||
|
| |||||||
| Mean | Kojic | >12.8 | 7.6 | 0.8 | >12.8 | 10.8 | 0.9 |
| H2O2 | 3.7 | 1.8 | 4.0 | 1.8 | |||
|
| |||||||
| Kojic | - | - | - | - | |||
| H2O2 | |||||||
MIC: Minimum inhibitory concentration, MFC: Minimum fungicidal concentration, FICI: Fractional Inhibitory Concentration Indices, FFCI: Fractional Fungicidal Concentration Indices. Student’s t-test for paired data (combined, i.e., chemosensitization) was vs. mean MIC or MFC of each compound (alone, i.e., no chemosensitization) determined in six strains. Calculation was based on [22].
Kojic acid was tested up to 12.8 mM. For calculation purpose, 25.6 mM (doubling of 12.8 mM) was used.
Figure 3(a) MFC determination of A. fumigatus strains (AF293, sakAΔ, mpkCΔ) with the treatment of kojic acid (KA) + H2O2. (b) MFC determination in A. fumigatus sakAΔ strain with the treatment of KA + AMB. Results indicated that A. fumigatus AF293 and mpkCΔ strains needed higher concentration of KA or AMB to achieve ≥99.9% cell death compared to sakAΔ. (c) MFC determination in Candida krusei ATCC6258 with the treatment of KA + AMB.
Antifungal chemosensitization of kojic acid (mM) with AMB (μg/mL) tested against Aspergillus and yeast strains. a MFCs are concentrations where ≥99.9% fungal death was achieved, except where noted in the Table.
| Strains | Compounds | MIC alone | MIC combined | FICI | MFC alone | MFC combined | FFCI |
|---|---|---|---|---|---|---|---|
| Kojic | >12.8 | 0.8 | 0.8 | >12.8 | 3.2 | 0.6 | |
| AF293 | AMB | 4 | 2 | >32 | 32 | (99.8% inhibition) | |
| Kojic | >12.8 | 12.8 | 1.0 | >12.8 | 0.4 | ||
| AMB | 2 | 1 | (85%–90% inhibition) | 4 | 2 | ||
| Kojic | >12.8 | 0.2 | >12.8 | 0.2 | |||
| AMB | 4 | 2 | 8 | 4 | |||
| Kojic | >12.8 | 6.4 | 0.8 | >12.8 | > 12.8 | 2.0 | |
| CAN276 | AMB | 1 | 0.5 | 1 | 1 | ||
| Kojic | >12.8 | 0.4 | >12.8 | 6.4 | 0.8 | ||
| ATCC 6258 | AMB | 2 | 1 | 2 | 1 | ||
| Kojic | >12.8 | 0.4 | >12.8 | 3.2 | 0.6 | ||
| AMB | 2 | 1 | 2 | 1 | |||
|
| |||||||
| Mean | Kojic | >12.8 | 3.5 | 0.7 | >12.8 | 6.5 | 0.8 |
| AMB | 2.5 | 1.3 | 13.5 | 6.8 | |||
|
| |||||||
| Kojic | - | - | - | - | |||
| AMB | |||||||
AMB: Amphotericin B. MIC: Minimum inhibitory concentration, MFC: Minimum fungicidal concentration. FICI: Fractional Inhibitory Concentration Indices, FFCI: Fractional Fungicidal Concentration Indices. Student’s t-test for paired data (combined, i.e., chemosensitization) was vs. mean MIC or MFC of each compound (alone, i.e., no chemosensitization) determined in six strains. Calculation was based on [22].
Kojic acid was tested up to 12.8 mM. For calculation purpose, 25.6 mM (doubling of 12.8 mM) was used.
AMB was tested up to 32 μg/mL. For calculation purpose, 64 μg/mL (doubling of 32 μg/mL) was used.
Antifungal chemosensitization of kojic acid (mM) with AMB (μg/mL). a MFCs are concentrations where ≥99.9% fungal death was achieved.
| Strains | Compounds | MIC alone | MIC combined | FICI | MFC alone | MFC combined | FFCI |
|---|---|---|---|---|---|---|---|
| Kojic | >12.8 | 6.4 | 0.8 | > 12.8 | 12.8 | 1.0 | |
| BY4741 | AMB | 2 | 1 | 4 | 2 | ||
| Kojic | >12.8 | 6.4 | 0.8 | > 12.8 | 12.8 | 1.0 | |
| AMB | 2 | 1 | 4 | 2 | |||
| Kojic | >12.8 | 6.4 | 0.8 | > 12.8 | 12.8 | 1.0 | |
| AMB | 2 | 1 | 4 | 2 | |||
|
| |||||||
| Mean | Kojic | >12.8 | 6.4 | 0.8 | > 12.8 | 12.8 | 1.0 |
| AMB | 2 | 1 | 4 | 2 | |||
|
| |||||||
| Kojic | - | - | - | - | |||
| AMB | |||||||
AMB: Amphotericin B. MIC: Minimum inhibitory concentration, MFC: Minimum fungicidal concentration. FICI: Fractional Inhibitory Concentration Indices, FFCI: Fractional Fungicidal Concentration Indices. Student’s t-test for paired data (combined, i.e., chemosensitization) was vs. mean MIC or MFC of each compound (alone, i.e., no chemosensitization) determined in three strains. Calculation was based on [22].
Kojic acid was tested up to 12.8 mM. For calculation purpose, 25.6 mM (doubling of 12.8 mM) was used.
Summary of responses of Aspergillus and yeast strains to the co-application of kojic acid with H2O2 or AMB. a
| Fungal strains | Agents co-applied | |
|---|---|---|
|
| ||
| H2O2 (FICI, FFCI) | AMB (FICI, FFCI) | |
|
| ||
| - | - | |
| - | - | |
| + ( | + (0.8, 0.6) | |
| + (1.0, 1.0) | + (1.0, | |
| + (1.0, 1.0) | + ( | |
| + (0.8, 0.8) | - | |
| + (0.8, 1.0) | - | |
| + (0.8, 1.0) | - | |
|
| ||
|
| ||
| - | - | |
| - | + (0.8, 2.0) | |
| - | + ( | |
| - | - | |
| - | - | |
| - | + ( | |
| - | + (0.8, 1.0) | |
| - | + (0.8, 1.0) | |
| - | + (0.8, 1.0) | |
+, enhancement of antifungal activity after co-application; -, no enhancement of antifungal activity after co-application.
FICI, Fractional Inhibitory Concentration Indices; FFCI, Fractional Fungicidal Concentration Indices; Both FICI and FFCI values were based on Tables 2–4; Bold: synergistic interaction.
Figure 4(a) Agar bioassay showing co-application of kojic acid (KA) could not overcome the tolerance of Aspergillus fumigatus sakAΔ and mpkCΔ mutants to fludioxonil (FLUD). None, no treatment control; FLUD 50 μM; KA 30 mM. (b) Agar bioassay showing co-application of KA enhanced the antifungal activity of strobilurin (Kre-Me) in A. fumigatus strains. None, no treatment control; Kre-Me 25 μM; KA 25 mM.